Milton Mayo Morris
Milton Mayo Morris's purchase track record
Milton Mayo Morris has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/8/2023 | MYO | $16K | +275.5% | +200.9% | +14.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
MYO appoints Mary-Katherine McClure as Chief Commercial Officer. Myomo announced that Mary‑Katherine McClure has been named chief commercial officer. McClure will lead the company’s sales and marketing efforts and oversee commercial strategy. The addition of an experienced executive comes as the stock is trading near a long‑standing support level.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Nordson Packaging Recovery Cited Amid Valuation Concerns. Recent commentary highlights a genuine recovery in Nordson's packaging segment, though analysts note the stock price reflects this optimism. The company trades at a trailing P/E of 32.8, which some view as a premium relative to its current valuation. With the stock near its 52-week high, the market is closely watching whether operational improvements can justify the current price point.
Transaction History
| EMBC | ▼ Sell | Open Market | 6,293 | $37K | 9/4/2026 | View on chart |
| MYO | ▼ Sell | Open Market | 15,000 | $21K | 9/2/2026 | View on chart |
| NDSN | ▼ Sell | Open Market | 156 | $49K | 9/2/2026 | View on chart |
| MYO | ▲ Buy | Grant | 78,704 | $0 | 6/25/2026 | View on chart |
| NDSN | ▼ Sell | Open Market | 245 | $67K | 4/15/2026 | View on chart |
| EMBC | ▲ Buy | Grant | 22,841 | $0 | 2/11/2026 | View on chart |
| NDSN | ▼ Sell | Open Market | 265 | $61K | 11/3/2025 | View on chart |
| NDSN | ▲ Buy | Grant | 822 | $191K | 11/1/2025 | View on chart |
| MYO | ▲ Buy | Grant | 29,720 | $0 | 6/11/2025 | View on chart |
| EMBC | ▼ Sell | Open Market | 3,100 | $51K | 2/13/2025 | View on chart |
| EMBC | ▲ Buy | Grant | 13,839 | $0 | 2/12/2025 | View on chart |
| NDSN | ▲ Buy | Grant | 747 | $186K | 11/1/2024 | View on chart |
| MYO | ▲ Buy | Grant | 12,034 | $0 | 6/5/2024 | View on chart |
| EMBC | ▲ Buy | Grant | 11,455 | $0 | 2/7/2024 | View on chart |
| MYO | ▲ Buy | Grant | 25,000 | $95K | 1/19/2024 | View on chart |
| NDSN | ▲ Buy | Grant | 749 | $158K | 11/1/2023 | View on chart |
| MYO | ▲ Buy | Open Market | 15,000 | $16K | 9/8/2023 | View on chart |
| MYO | ▲ Buy | Grant | 59,988 | $0 | 6/28/2023 | View on chart |
| EMBC | ▲ Buy | Grant | 6,979 | $0 | 2/9/2023 | View on chart |
| NDSN | ▲ Buy | Grant | 730 | $165K | 11/1/2022 | View on chart |
| NDSN | ▲ Buy | Grant | 78 | $17K | 9/15/2022 | View on chart |
| EMBC | ▲ Buy | Grant | 6,024 | $0 | 4/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Concentra Group Hits 52-Week High Amid Medical Services Trends
Concentra Group Holdings, the parent company of Embecta, recently reached a 52-week high, prompting questions about the sustainability of this price movement. This development is relevant to Embecta shareholders as it reflects broader sentiment in the medical services sector. Embecta itself trades with a low trailing P/E of 3.7 and offers a dividend yield of 3.43%, while its stock remains significantly below its 52-week high of $14.91.
Concentra Group Hits 52-Week High Amid Medical Services Trends. Concentra Group Holdings, the parent company of Embecta, recently reached a 52-week high, prompting questions about the sustainability of this price movement. This development is relevant to Embecta shareholders as it reflects broader sentiment in the medical services sector. Embecta itself trades with a low trailing P/E of 3.7 and offers a dividend yield of 3.43%, while its stock remains significantly below its 52-week high of $14.91.